Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating JCAR017 (lisocabtagene maraleucel) in adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• JCAR017

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: ACTIVE_NOT_RECRUITING